Workstream Type: Policy Comments
Formal responses to government RFIs
-
Incentives for Rare Diseases: the Right Healthcare Priorities?
-
Dissecting PhRMA’s Opposition to H.R. 3 Lower Drug Costs Now Act of 2019
-
Dr. Bach Testifies at U.S. Senate Committee on Finance’s First Hearing of Session
-
Competitive Acquisition Program
-
TEDMED Talk: Changing the Drug Pricing Game with Dr. Peter Bach
-
DPL Responds to CMS Proposed Changes to OPPS Policy
-
DPL Responds to HHS RFI for IPI Drug Pricing Model (Nov. 30, 2018)
-
DPL responds to HHS Blueprint (May 16, 2018)
-
The Price Tag on Progress — Chemotherapy for Colorectal Cancer